By FieldPulse Editorial · March 25, 2026
Tags: Clinical Trials, Pipeline
Maze Therapeutics reported a 61.8% reduction in proteinuria in a key patient subgroup for its APOL1 kidney disease drug — but investors punished the stock over trial size and competition from Vertex Pharmaceuticals.
Sometimes strong clinical data and a collapsing stock price arrive in the same press release. That was the situation facing Maze Therapeutics on March 25, when the company reported Phase 2 HORIZON trial results for MZE829, its APOL1 inhibitor for APOL1-mediated kidney disease (AMKD) — and watched its market cap fall roughly 31 percent by the end of the day. The data themselves were not the problem. In the broad HORIZON trial population, MZE829 produced a 35.6 percent mean reduction in urine albumin-to-creatinine ratio (uACR) — a standard measure of proteinuria and kidney damage — at 12 weeks.